More significantly, K5+/K19+ cell line over-expressing either mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR had statistically significant lower lung metastasis latency (Figure 5B, Supplementary Table 6) as compared to K5+/K19− with mRas/mp53/wtErbB2, higher lung metastasis incidence (Table 3, Supplementary Table 3) and bigger metastatic tumors (Figure 5D) as compared to K5+/K19− cells over-expressing either of the oncogene combinations, indicating that the nature of cell type also affects the tumor and metastasis formation. The gene discussed is KRT5; the disease is metastatic neoplasm.